Heparin for the treatment of thrombosis in preterm and term neonates

Olga Romantsik, Matteo Bruschettini, Simona Zappettini, Luca Antonio Ramenghi, Maria Grazia Calevo

Research output: Contribution to journalArticlepeer-review


This is the protocol for a review and there is no abstract. The objectives are as follows: To assess whether heparin treatment (both UFH and LMWH) in preterm and term newborn infants with diagnosed thrombosis reduces the rate of mortality and morbidity. The intervention will be compared to placebo or no treatment. In addition, the safety of heparin therapy (both UFH and LMWH) will be assessed for potential harms. Subgroup analyses will be performed regarding gestational age, birth weight, mode of thrombus diagnosis, presence of central line, positive family history for genetic disorders (thrombophilia, deficiency of protein S and protein C, MTHFR mutation), route of heparin administration, type of heparin used, and location of thrombus (see Subgroup analysis and investigation of heterogeneity).

Original languageEnglish
Article numberCD012185
JournalThe Cochrane database of systematic reviews
Issue number5
Publication statusPublished - May 5 2016

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology (medical)


Dive into the research topics of 'Heparin for the treatment of thrombosis in preterm and term neonates'. Together they form a unique fingerprint.

Cite this